HRP20171917T1 - Terapeutski pripravci koji sadrže macitentan - Google Patents
Terapeutski pripravci koji sadrže macitentan Download PDFInfo
- Publication number
- HRP20171917T1 HRP20171917T1 HRP20171917TT HRP20171917T HRP20171917T1 HR P20171917 T1 HRP20171917 T1 HR P20171917T1 HR P20171917T T HRP20171917T T HR P20171917TT HR P20171917 T HRP20171917 T HR P20171917T HR P20171917 T1 HRP20171917 T1 HR P20171917T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- butoxy
- isopropyl
- Prior art date
Links
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title claims 5
- 229960001039 macitentan Drugs 0.000 title claims 5
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 14
- 102000009079 Epoprostenol Receptors Human genes 0.000 claims 11
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 11
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 2
- 102000002045 Endothelin Human genes 0.000 claims 2
- 108050009340 Endothelin Proteins 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 229960002890 beraprost Drugs 0.000 claims 2
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 2
- 229960002240 iloprost Drugs 0.000 claims 2
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- -1 5,6-diphenylpyrazin-2yl Chemical group 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Proizvod koji sadrži macitentan ili farmaceutski prihvatljivu sol navedenog spoja, u kombinaciji s barem jednim spojem koji ima osobine agonista prostaciklinskog receptora (IP), ili njegovom farmaceutski prihvatljivom soli, naznačen time da je spoj koji ima osobine agonista prostaciklinskog receptora (IP) odabran od iloprosta i njegovih farmaceutski prihvatljivih soli, beraprosta i njegovih farmaceutski prihvatljivih soli, 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N(metilsulfonil)acetamida i njegovih farmaceutski prihvatljivih soli, i {4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}octene kiseline, i njezinih farmaceutski prihvatljivih soli.
2. Proizvod prema zahtjevu 1, naznačen time da je spoj koji ima osobine agonista prostaciklinskog receptora (IP) odabran od 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N-(metilsulfonil)acetamida i njegovih farmaceutski prihvatljivih soli i {4-[(5,6-difenilpirazin-2il)(izopropil)amino]butoksi}octene kiseline i njezinih farmaceutski prihvatljivih soli.
3. Proizvod prema zahtjevu 2, naznačen time da je spoj koji ima agonista prostaciklinskog receptora (IP) 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N(metilsulfonil)acetamid ili njegova farmaceutski prihvatljiva sol.
4. Proizvod koji sadrži macitentan ili farmaceutski prihvatljivu sol ovog spoja, u kombinaciji s barem jednim spojem koji ima osobine agonista prostaciklinskog receptora (IP), ili njegove farmaceutski prihvatljive soli za terapeutsku upotrebu, simultanu, odvojenu ili tijekom vremenskog perioda, za liječenje bolesti u koju je uključen endotelin, odabrane od hipertenzije, plućne hipertenzije, dijabetičke arteriopatije, prestanka rada srca, erektilne disfunkcije, angine pektoris i plućne fibroze, pri čemu je spoj koji ima osobine agonista prostaciklinskog receptora (IP) odabran od iloprosta i njegovih farmaceutski prihvatljivih soli, beraprosta i njegovih farmaceutski prihvatljivih soli, 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N-(metilsulfonil)acetamida i njegovih farmaceutski prihvatljivih soli i {4-[(5,6-difenilpirazin-2il)(izopropil)amino]butoksi}octene kiseline i njezinih farmaceutski prihvatljivih soli.
5. Proizvod za upotrebu prema zahtjevu 4, naznačen time da je spoj koji ima osobine agonista prostaciklinskog receptora (IP) odabran od 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N-(metilsulfonil)acetamida i njegovih farmaceutski prihvatljivih soli, i {4-[(5,6-difenilpirazin-2il)(izopropil)amino]butoksi}octene kiseline i i njenih farmaceutski prihvatljivih soli.
6. Proizvod za upotrebu prema zahtjevu 5, naznačen time da je spoj koji ima osobine agonista prostaciklinskog receptora (IP) 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N(metilsulfonil)acetamid ili njegova farmaceutski prihvatljiva sol.
7. Proizvod za upotrebu prema jednom od zahtjeva 4 do 6, naznačen time da je bolest plućna hipertenzija.
8. Farmaceutski pripravak naznačen time da sadrži, kao aktivnu tvar, macitentan, ili njegovu farmaceutski prihvatljivu sol, u kombinaciji s barem jednim spojem koji ima osobine agonista prostaciklinskog receptora (IP), ili njegove farmaceutski prihvatljive soli, kao i barem jedan farmaceutski prihvatljivi ekscipijent, pri čemu je spoj koji ima osobine agonista prostaciklinskog receptora (IP) ili njegove farmaceutski prihvatljive soli 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N(metilsulfonil)acetamid ili njegova farmaceutski prihvatljiva sol.
9. Upotreba macitentana, ili njegove farmaceutski prihvatljive soli, u kombinaciji s barem jednim spojem koji ima osobine agonista prostaciklinskog receptora (IP), ili njegove farmaceutski prihvatljive soli, za proizvodnju lijeka za liječenje bolesti u koju je uključen endotelin, odabrane od hipertenzije, plućne hipertenzije, dijabetične arteriopatije, prestanka rada srca, erektilne disfunkcije, angine pektoris i plućne fibroze, pri čemu je spoj koji ima osobine agonista receptora prostaciklina (IP) ili njegove farmaceutski prihvatljive soli 2{4[(5,6difenilpirazin-2il)(izopropil)amino]butoksi}-N(metilsulfonil)acetamid ili njegova farmaceutski prihvatljiva sol.
10. Upotreba prema zahtjevu 9, naznačena time da je bolest koja se liječi plućna hipertenzija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2008053252 | 2008-08-13 | ||
| PCT/IB2009/053553 WO2010018549A2 (en) | 2008-08-13 | 2009-08-12 | Therapeutic compositions containing macitentan |
| EP09786912.7A EP2315587B1 (en) | 2008-08-13 | 2009-08-12 | Therapeutic compositions containing macitentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171917T1 true HRP20171917T1 (hr) | 2018-02-09 |
Family
ID=41346591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171917TT HRP20171917T1 (hr) | 2008-08-13 | 2017-12-11 | Terapeutski pripravci koji sadrže macitentan |
| HRP20192204TT HRP20192204T1 (hr) | 2008-08-13 | 2019-12-06 | Terapeutski sastavi koji sadrže macitentan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192204TT HRP20192204T1 (hr) | 2008-08-13 | 2019-12-06 | Terapeutski sastavi koji sadrže macitentan |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8809334B2 (hr) |
| EP (2) | EP3300729B1 (hr) |
| JP (3) | JP5764061B2 (hr) |
| KR (1) | KR101678699B1 (hr) |
| CN (1) | CN102099026B (hr) |
| AR (1) | AR073031A1 (hr) |
| AU (1) | AU2009280843B2 (hr) |
| BR (1) | BRPI0917661B8 (hr) |
| CA (1) | CA2731370C (hr) |
| CY (2) | CY1119826T1 (hr) |
| DK (2) | DK2315587T3 (hr) |
| ES (2) | ES2763176T3 (hr) |
| HK (1) | HK1253355B (hr) |
| HR (2) | HRP20171917T1 (hr) |
| HU (2) | HUE036071T2 (hr) |
| IL (1) | IL211143A0 (hr) |
| LT (2) | LT3300729T (hr) |
| MA (1) | MA32614B1 (hr) |
| MX (1) | MX350011B (hr) |
| MY (1) | MY178894A (hr) |
| NO (1) | NO2315587T3 (hr) |
| NZ (1) | NZ591601A (hr) |
| PL (2) | PL3300729T3 (hr) |
| PT (2) | PT3300729T (hr) |
| RU (1) | RU2519161C2 (hr) |
| SI (2) | SI3300729T1 (hr) |
| TW (1) | TWI446911B (hr) |
| WO (1) | WO2010018549A2 (hr) |
| ZA (1) | ZA201101900B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080233188A1 (en) | 2005-09-12 | 2008-09-25 | Actelion Pharmaceuticals Ltd. | Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| PL2246336T3 (pl) | 2008-02-28 | 2020-12-14 | Nippon Shinyaku Co., Ltd. | Inhibitor zwłóknienia |
| PL3300729T3 (pl) | 2008-08-13 | 2020-04-30 | Actelion Pharmaceuticals Ltd | Kompozycje terapeutyczne zawierające macitentan |
| US9371264B2 (en) | 2013-01-11 | 2016-06-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9794795B1 (en) | 2016-04-29 | 2017-10-17 | Corning Optical Communications Wireless Ltd | Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS |
| RU2019121646A (ru) | 2016-12-14 | 2021-01-15 | Респира Терапьютикс, Инк. | Способы и композиции для лечения легочной гипертензии и других заболеваний легких |
| MA54522A (fr) | 2018-12-21 | 2022-03-23 | Actelion Pharmaceuticals Ltd | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4539333A (en) | 1976-05-11 | 1985-09-03 | Burroughs Wellcome Co. | Prostacyclin, methods of using and method of making |
| DE2845770A1 (de) | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| US4683330A (en) | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| EP1345920B1 (en) | 2000-12-18 | 2006-04-12 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| CA2431077A1 (en) * | 2000-12-19 | 2002-06-27 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| DE10100426B4 (de) | 2001-01-08 | 2006-04-06 | Steag Hamatech Ag | Verfahren und Vorrichtung zum Zusammenfügen von Substraten |
| TWI316055B (hr) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2004017993A1 (en) | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| ES2320649T3 (es) | 2002-12-02 | 2009-05-27 | Actelion Pharmaceuticals Ltd. | Pirimidin-sulfamidas y su uso como antagonistas de receptores de endotelina. |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| US20080233188A1 (en) | 2005-09-12 | 2008-09-25 | Actelion Pharmaceuticals Ltd. | Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| ES2446303T3 (es) | 2008-02-20 | 2014-03-07 | Actelion Pharmaceuticals Ltd. | Combinación que comprende paclitaxel para el tratamiento del cáncer de ovarios |
| PL3300729T3 (pl) | 2008-08-13 | 2020-04-30 | Actelion Pharmaceuticals Ltd | Kompozycje terapeutyczne zawierające macitentan |
-
2009
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh active Active
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/en active
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja active Active
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en active Active
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active IP Right Grant
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt active IP Right Grant
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en active Application Filing
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en active Active
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
-
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
-
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
-
2015
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
-
2017
- 2017-12-11 HR HRP20171917TT patent/HRP20171917T1/hr unknown
-
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/zh unknown
-
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171917T1 (hr) | Terapeutski pripravci koji sadrže macitentan | |
| HRP20201352T1 (hr) | Inhibitor fibroze | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2011201907A5 (hr) | ||
| HRP20200665T1 (hr) | Bifenilsulfonamidni antagonist receptora za endotelin i angiotenzin ii za liječenje glomeruloskleroze i iga-inducirane nefropatije | |
| RU2020123679A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| HRP20160997T1 (hr) | Liječenje poremećaja povezanih s bdnf primjenom lakvinimoda | |
| HRP20160327T1 (hr) | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom | |
| SI2600851T1 (en) | PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT | |
| HRP20161082T1 (hr) | Sistemno liječenje od parazita koji sišu i konzumiraju krv oralnom primjenom parazitocida | |
| JP2023017050A5 (hr) | ||
| UY32833A (es) | Antagonistas dp2 y usos del mismo | |
| EA200702020A1 (ru) | Новые соединения, их изомеры или фармацевтически приемлемые соли в качестве антагонистов ваниллоидных рецепторов и содержащие их фармацевтические композиции | |
| HRP20120798T1 (hr) | Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva | |
| JP2013520405A5 (hr) | ||
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| JP2005516904A5 (hr) | ||
| HK1131984A1 (en) | Substituted carboxamides as group i metabotropic receptor antagonists | |
| HRP20150387T1 (hr) | Sol kolina i trometamina od likofelona | |
| JP2006517557A5 (hr) | ||
| MA32722B1 (fr) | Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion | |
| JP2011157395A5 (hr) | ||
| RU2011145436A (ru) | Композиции с немедленным высвобождением лекарственного средства |